Héloïse Bourien1, Xavier Palard2, Yan Rolland3, Fanny Le Du1, Luc Beuzit4, Thomas Uguen5, Samuel Le Sourd1, Marc Pracht1, Vincent Manceau2, Astrid Lièvre6, Karim Boudjema7, Etienne Garin2,8, Julien Edeline9,10. 1. Medical Oncology, Centre Eugène Marquis, Rennes, France. 2. Nuclear Medicine, Centre Eugène Marquis, Rennes, France. 3. Interventional Radiology, Centre Eugène Marquis, Rennes, France. 4. Radiology, CHU Pontchaillou, Rennes, France. 5. Hepatology, CHU Pontchaillou, Rennes, France. 6. Gastroenterology, CHU Pontchaillou, Rennes, France. 7. Hepatobiliary Surgery, CHU Pontchaillou, Rennes, France. 8. Univ Rennes, INSERM, INRA, Centre de Lutte contre le Cancer Eugène Marquis, Institut NUMECAN (Nutrition Metabolisms and Cancer), F-35000, Rennes, France. 9. Medical Oncology, Centre Eugène Marquis, Rennes, France. j.edeline@rennes.unicancer.fr. 10. Univ Rennes, INSERM, INRA, Centre de Lutte contre le Cancer Eugène Marquis, Institut NUMECAN (Nutrition Metabolisms and Cancer), F-35000, Rennes, France. j.edeline@rennes.unicancer.fr.
Abstract
PURPOSE: Radioembolization (RE) is a promising treatment option for biliary tract cancers (BTC). We report here the largest series to date using this treatment modality. METHODS: We retrospectively studied data from 64 patients treated outside prospective clinical trial at our institution. We studied baseline characteristics as potential prognostic factors. We studied dose delivered to the tumor as predictive factors of outcomes in patients not receiving concomitant chemotherapy. RESULTS: The Progression-Free Survival and Overall Survival (OS) were 7.6 months [95% Confidence Interval (CI): 4.6-10.6] and 16.4 months [95% CI: 7.8-25.0] in the whole cohort. The factors independently associated with OS in multivariable analysis were the primary localization of ICC (HR = 0.27, 95% CI: 0.11-0.68, p = 0.005) and a PS > 0 (HR = 2.21, 95% CI: 1.11-4.38, p = 0.024). During follow-up, 12 patients (19%) underwent surgery following downstaging, with a median OS of 51.9 months. In patients not treated with concomitant chemotherapy (n = 31), OS was significantly higher in patients with a dose delivered to the tumor 260Gy or higher than in patients with a dose delivered to the tumor lower than 260Gy (median 28.2 vs 11.4 months, log-rank p = 0.019). CONCLUSION: Our results confirm that RE is a promising treatment modality in BTC. A high proportion of patients could be downstaged to surgery, with promising long-term survival. Dose delivered to the tumor correlated with clinical outcomes when chemotherapy was not used concomitantly.
PURPOSE: Radioembolization (RE) is a promising treatment option for biliary tract cancers (BTC). We report here the largest series to date using this treatment modality. METHODS: We retrospectively studied data from 64 patients treated outside prospective clinical trial at our institution. We studied baseline characteristics as potential prognostic factors. We studied dose delivered to the tumor as predictive factors of outcomes in patients not receiving concomitant chemotherapy. RESULTS: The Progression-Free Survival and Overall Survival (OS) were 7.6 months [95% Confidence Interval (CI): 4.6-10.6] and 16.4 months [95% CI: 7.8-25.0] in the whole cohort. The factors independently associated with OS in multivariable analysis were the primary localization of ICC (HR = 0.27, 95% CI: 0.11-0.68, p = 0.005) and a PS > 0 (HR = 2.21, 95% CI: 1.11-4.38, p = 0.024). During follow-up, 12 patients (19%) underwent surgery following downstaging, with a median OS of 51.9 months. In patients not treated with concomitant chemotherapy (n = 31), OS was significantly higher in patients with a dose delivered to the tumor 260Gy or higher than in patients with a dose delivered to the tumor lower than 260Gy (median 28.2 vs 11.4 months, log-rank p = 0.019). CONCLUSION: Our results confirm that RE is a promising treatment modality in BTC. A high proportion of patients could be downstaged to surgery, with promising long-term survival. Dose delivered to the tumor correlated with clinical outcomes when chemotherapy was not used concomitantly.
Authors: Nathaniel C Swinburne; Derek M Biederman; Cecilia Besa; Nora E Tabori; Aaron M Fischman; Rahul S Patel; Francis Scott Nowakowski; Ganesh Gunasekaran; Myron E Schwartz; Robert A Lookstein; Edward Kim Journal: Cancer Biother Radiopharm Date: 2017-06-09 Impact factor: 3.099
Authors: Ralf-T Hoffmann; Philipp M Paprottka; Agnes Schön; Fabian Bamberg; Alexander Haug; Eva-Maria Dürr; Barbara Rauch; Christoph T Trumm; Tobias F Jakobs; Thomas K Helmberger; Maximilian F Reiser; Frank T Kolligs Journal: Cardiovasc Intervent Radiol Date: 2011-03-24 Impact factor: 2.740
Authors: Tamer M Shaker; Chloe Chung; Manish K Varma; Michael G Doherty; Andrea M Wolf; Mathew H Chung; M Mura Assifi Journal: Am J Surg Date: 2018-02-02 Impact factor: 2.565
Authors: Matthias P Fabritius; Najib Ben Khaled; Wolfgang G Kunz; Jens Ricke; Max Seidensticker Journal: J Clin Med Date: 2021-11-26 Impact factor: 4.241
Authors: Camille Goislard de Monsabert; Yann Touchefeu; Boris Guiu; Boris Campillo-Gimenez; Olivier Farges; David Tougeron; Isabelle Baumgaertner; Ahmet Ayav; Luc Beuzit; Marc Pracht; Astrid Lièvre; Samuel Le Sourd; Karim Boudjema; Yan Rolland; Etienne Garin; Eveline Boucher; Julien Edeline Journal: Curr Oncol Date: 2021-11-08 Impact factor: 3.677
Authors: M Weber; M Lam; C Chiesa; M Konijnenberg; M Cremonesi; P Flamen; S Gnesin; L Bodei; T Kracmerova; M Luster; E Garin; K Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2022-02-11 Impact factor: 9.236
Authors: Michael Köhler; Fabian Harders; Fabian Lohöfer; Philipp M Paprottka; Benedikt M Schaarschmidt; Jens Theysohn; Ken Herrmann; Walter Heindel; Hartmut H Schmidt; Andreas Pascher; Lars Stegger; Kambiz Rahbar; Moritz Wildgruber Journal: J Clin Med Date: 2019-12-25 Impact factor: 4.241
Authors: Romaric Loffroy; Maxime Ronot; Michel Greget; Antoine Bouvier; Charles Mastier; Christian Sengel; Lambros Tselikas; Dirk Arnold; Geert Maleux; Jean-Pierre Pelage; Olivier Pellerin; Bora Peynircioglu; Bruno Sangro; Niklaus Schaefer; María Urdániz; Nathalie Kaufmann; José Ignacio Bilbao; Thomas Helmberger; Valérie Vilgrain Journal: Cardiovasc Intervent Radiol Date: 2020-09-25 Impact factor: 2.740